Invivyd doses first participants in Phase 3 LIBERTY trial of VYD2311 vs mRNA COVID vaccine
PUBT · 06/09 11:02
Share
Listen to the news
- Invivyd dosed the first participants in LIBERTY, a Phase 3 head-to-head trial of its VYD2311 antibody versus an mRNA COVID-19 vaccine.
- Topline results have not been presented; reporting is expected in Q3 2026, alongside anticipated data from the pivotal DECLARATION trial.
- Study aims to compare short-term tolerability, focusing on side effects and reactions, to position VYD2311 as a vaccine alternative.
- Trial also evaluates co-administration with an mRNA vaccine, testing whether combined use remains acceptable from a safety and immune-response perspective.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606090701PRIMZONEFULLFEED9733793) on June 09, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved